Результаты поиска

Risk of Early Mortality in Patients With Newly Diagnosed Multiple Myeloma.

The overall survival of patients with multiple myeloma (MM) has been improved greatly over the last 2 decades with the broader use of novel drugs and autologous tandem transplantation. However, more than one tenth of myeloma patients still die shortly after diagnosis. We therefore aim to investigate the risk factors of early mortality (death within 60 days after diagnosis) in patients with MM. We included in this study 451 consecutive patients with MM, newly diagnosed at an Asian tertiary medical center between January 1, 2002 and April 30, 2015. A total of 57 subjects who experienced early mo

Неучтенная роль экгасомов в когнитивно-моторной нейрореабилитации: систематический обзор.

Эксгармии — это новые инструменты когнитивно-моторной нейрореабилитации, но их воздействие на взрослых с неврологическими условиями еще недостаточно изучено. В рамках этого систематического обзора были изучены исследования, полученные из PubMed, Scopus, Embase и Web of Science, с оценкой воздействия экзотомов на двигательные и когнитивные результаты. К числу приемлемых исследований относятся случайные контролируемые испытания (РСТ), не связанные с РСТС и экспериментальные проекты. Протокол был зарегистрирован на сайте ПРОСПЕРО (CRD420250655053) и составлен в соответствии с руководящими принцип

Quantitative systems pharmacology modeling sheds light into the dose response relationship of a trispecific T cell engager in multiple myeloma.

In relapsed and refractory multiple myeloma (RRMM), there are few treatment options once patients progress from the established standard of care. Several bispecific T-cell engagers (TCE) are in clinical development for multiple myeloma (MM), designed to promote T-cell activation and tumor killing by binding a T-cell receptor and a myeloma target. In this study we employ both computational and experimental tools to investigate how a novel trispecific TCE improves activation, proliferation, and cytolytic activity of T-cells against MM cells. In addition to binding CD3 on T-cells and CD38 on tumo

CAR-T cell therapy for cancer: current challenges and future directions.

Chimeric antigen receptor T (CAR-T) cell therapies have transformed the treatment of relapsed/refractory (R/R) B-cell malignancies and multiple myeloma by redirecting activated T cells to CD19- or BCMA-expressing tumor cells. However, this approach has yet to be approved for acute myeloid leukemia (AML), the most common acute leukemia in adults and the elderly. Simultaneously, CAR-T cell therapies continue to face significant challenges in the treatment of solid tumors. The primary challenge in developing CAR-T cell therapies for AML is the absence of an ideal target antigen that is both effec

Natural Killer Cells: Angels and Devils for Immunotherapy.

In recent years, the relevance of the immune system to fight cancer has led to the development of immunotherapy, including the adoptive cell transfer of immune cells, such as natural killer (NK) cells and chimeric antigen receptors (CAR)-modified T cells. The discovery of donor NK cells' anti-tumor activity in acute myeloid leukemia patients receiving allogeneic stem cell transplantation (allo-SCT) was the trigger to conduct many clinical trials infusing NK cells. Surprisingly, many of these studies did not obtain optimal results, suggesting that many different NK cell parameters combined with

A Novel Approach to Prognostic Factors and Risk Stratification in Pediatric AML: Case Report and Literature Review.

Acute myeloid leukemia (AML), the second most common type of leukemia in children, is a heterogeneous disease known to be caused by genetic, epigenetic, and transcriptional changes, predominantly somatic and germline abnormalities. Despite significant improvement of overall survival rates, the prognosis of pediatric AML remains unfavorable in comparison with acute lymphoblastic leukemia (ALL), especially in relapsed or refractory settings. The current status and future directions are focused on establishing an accurate diagnosis and treatment strategies based on the genomic background. Next-ge

COVID-19 Vaccination in Cancer Patients: A Review Article.

Coronavirus disease 2019 (COVID-19) infection is caused by severe acute respiratory syndrome coronavirus 2. Adults with cancer are immunocompromised due to several causes including cancer itself and immunosuppressive therapy. Thus, cancer patients are more susceptible to develop COVID-19 infection. As COVID-19 vaccines became available, patients with cancer would benefit from receiving the vaccine. This article aims to review the recent evidences and recommendations about COVID-19 vaccination in cancer patients.Current guidelines recommend that patients with cancer should have the priority to

Genome-edited allogeneic CAR-T cells: the next generation of cancer immunotherapies.

Chimeric Antigen Receptor T (CAR-T) cell therapy has revolutionized cancer immunotherapy, particularly in hematological malignancies. However, the clinical application of autologous CAR-T cells faces significant high cost and manufacturing challenges. Universal allogeneic CAR-T cells, derived from healthy donors, represent a promising solution to these obstacles. These "off-the-shelf" therapies aim to reduce the complexity and cost of CAR-T production. Despite exciting advancements in genome-editing technologies and promising clinical trial data, significant challenges remain, including graft-

On CAR-Ts, decentralized in-house models, and the hospital exception. Routes for sustainable access to innovative therapies.

Chimeric Antigen Receptor T cells, or CAR-Ts, are a novel class of gene and cell 'one-shot' therapies based upon collecting, reprogramming, and using patients' own immune cells to treat their cancer. The article discusses the status, prospects, and some relevant legal issues of this frontier of personalized medicine. In particular, it explores the legitimacy of 'in-house' CAR-Ts, ie treatments manufactured and delivered to patients within the same clinical center by relying upon automated cell processing systems, a decentralized model which is very different from the one currently adopted for

Treatment decision making (TDM): a qualitative study exploring the perspectives of patients with chronic haematological cancers.

OBJECTIVES: Haematological malignancies are the fifth most common cancer in the UK, with chronic subtypes comprising around a third of all new diagnoses. These complex diseases have some similarities with other cancers, but often require different management. Surgical resection is not possible, and while some are curable with intensive chemotherapy, most indolent subtypes are managed with non-aggressive intermittent or continuous treatment, often over many years. Little is known about the views of patients with chronic haematological cancers regarding treatment decision making (TDM), a deficit

Immunotherapy of Multiple Myeloma: Promise and Challenges.

Whereas the treatment of MM was dependent solely on alkylating agents and corticosteroids during the prior three decades, the landscape of therapeutic measures to treat the disease began to expand enormously early in the current century. The introduction of new classes of small-molecule drugs, such as proteasome blockers (bortezomib and carfilzomib), immunomodulators (lenalidomide and pomalidomide), nuclear export inhibitors (selinexor), and histone deacetylase blockers (panobinostat), as well as the application of autologous stem cell transplantation (ASCT), resulted in a seismic shift in how

The Proceedings of the 19th International Cancer Imaging Society Meeting and Annual Teaching Course : Verona, Italy. 7 - 9 October 2019.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Navigating family life in the face of parental cancer: a qualitative study.

PurposeParental cancer can significantly impact family dynamics, particularly for adolescents and young adults (AYAs), who face the developmental task of balancing autonomy and connectedness. As cancer incidence rises globally, more AYAs are confronted with the challenges of parental illness. While most research focuses on individual psychological outcomes, less is known about how families function as a unit under such stress. This study aimed to gain deeper insight into family functioning, with a specific focus on autonomy, connectedness, and communication, in the face of parental cancer.Meth

Customized Marketing Strategies for Cancer Immunocyte Therapy Based on its Distinctive Attributes.

Cancer constitutes a persistent global health challenge, and immunocyte therapy has emerged as one approach in oncological care. This narrative review aimed to systematically analyze, synthesize, and critically interpret the therapeutic characteristics, advantages, market landscape, and current access barriers of cancer immunocyte therapy, based on thematic clustering and cross‑study integration of clinical evidence, market data, and industry reports. Immunocyte therapy exhibits distinctive features including personalization, long‑term immune memory, and observed efficacy in refractory maligna

Breaking through Multiple Myeloma: A Paradigm for a Comprehensive Tumor Ecosystem Targeting.

Multiple myeloma (MM) is a cancerous condition characterized by the proliferation of plasma cells within the hematopoietic marrow, resulting in multiple osteolytic lesions. MM patients typically experience bone pain, kidney damage, fatigue due to anemia, and infections. Historically, MM was an incurable disease with a life expectancy of around three years after diagnosis. However, over the past two decades, the development of novel therapeutics has significantly improved patient outcomes, including response to treatment, remission duration, quality of life, and overall survival. These advancem

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma.

Outcomes in multiple myeloma (MM) have improved dramatically in the last two decades with the advent of novel therapies including immunomodulatory agents (IMiDs), proteasome inhibitors and monoclonal antibodies. In recent years, immunotherapy for the treatment of MM has advanced rapidly, with the approval of new targeted agents and monoclonal antibodies directed against myeloma cell-surface antigens, as well as maturing data from late stage trials of chimeric antigen receptor CAR T cells. Therapies that engage the immune system to treat myeloma offer significant clinical benefits with durable

Корреляция когнитивных дисфункций и мер по диффузионному измерению МРТ в предметах, имеющих ОРД.

КОЛИЧЕСТВО: Когнитивная дисфункция - это обычное нарушение, наблюдаемое у лиц с множественным склерозом (MS), затрагивающее такие ключевые области, как внимание, скорость обработки информации, память и исполнительные функции. Этот дефицит, как правило, выявляется на основе всеобъемлющих нейропсихологических оценок, которые представляют собой золотой стандарт для когнитивной оценки. В последние годы были активизированы усилия по интеграции нейропсихологических результатов с передовыми методами нейроимации, с тем чтобы лучше понять нейронные субстраты когнитивной дисфункции. Среди них Difsusion

Совпадение в полном тексте источника
… The hippocampus, a critical hub for memory consolidation, also demonstrated significant DTI alterations, with increased MD correlating negatively with global cognitive performance ( Gu et al., 2022 ). …

Полимеризация тубулинов, пропагандирующая протеины: функциональное разнообразие с последствиями в неврологических расстройствах.

Полимеризация тубулинов, пропагандирующая протеины (ПППН), в значительной степени сохраняется в различных видах, но по-прежнему недостаточно изучена. В организме человека есть три гена ТППЦ, и только один гомологический ген ТППЦ у беспозвоночных, таких как Дрософила и К. Элеган. TPPP человека (TPPP1/p25/p25α) обогащается в мозгу и имеет сходство с беспозвоночными TPPP. TPPP/p25 ассоциируется с микротубулями и играет ключевую роль в динамике микротубуля, слиянии и полимеризации, тем самым стабилизируя микротубулярную сеть. Это крайне важно для организации цитоскелета и надлежащего функционирова

Совпадение в полном тексте источника
… In vivo interactions between Complexin and TPPP were reported from studies on spatial learning and memory consolidation performed in the rat hippocampus (Nelson et al.  2004 ). …

Поощрение использования продольных электронных медицинских записей: обучение по изучению реальных мировых данных о последствиях хронических заболеваний.

Для борьбы с хроническими заболеваниями требуется постоянный мониторинг деятельности по борьбе с заболеваниями и терапевтическое реагирование в целях оптимизации планов лечения. С учетом растущей доступности методов лечения, позволяющих сглаживать заболевания, крайне важно изучить вопрос о сравнительной эффективности и долгосрочных результатах, помимо тех, которые могут быть получены в ходе выборочных клинических испытаний. Мы внедряем всеобъемлющий трубопровод для получения воспроизводимых и обобщенных реальных данных о результатах болезней за счет использования электронных данных о состоянии

Hematopoeitic Cell Transplantation and CAR T-Cell Therapy: Complements or Competitors?

Allogeneic hematopoietic cell transplantation (allo-HCT) and chimeric antigen receptor T cell (CAR T) therapy are the main modalities of adoptive cellular immunotherapy that have widely permeated the clinical space. The advent of both technologies revolutionized treatment of many hematologic malignancies, both offering the chance at sustained remissions for patients who would otherwise invariably succumb to their diseases. The understanding and exploitation of the nonspecific alloreactivity of allo-HCT and the graft-versus-tumor effect is contrasted by the genetically engineered precision of C